Market Summary
USD5.18-0.25
Market Closed-4.60%
ADPT Alerts
ADPT Stock Price
ADPT RSI Chart
ADPT Valuation
ADPT Price/Sales (Trailing)
ADPT Profitability
ADPT Fundamentals
ADPT Revenue
ADPT Earnings
Price Action
52 Week Range
5.1010.79
(Low)(High)
Last 7 days
-21.0%
Last 30 days
-19.6%
Last 90 days
-28.2%
Trailing 12 Months
-31.6%
ADPT Financial Health
ADPT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ADPT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-08 | SOOD NITIN | sold | -68,997 | 6.54 | -10,550 | chief commercial officer, mrd |
2023-08-07 | SOOD NITIN | sold | -38,320 | 6.78 | -5,652 | chief commercial officer, mrd |
2023-06-20 | PETERSON TYCHO | acquired | 985,215 | 7.3 | 134,961 | chief financial officer |
2023-06-20 | PETERSON TYCHO | sold | -1,098,580 | 8.14 | -134,961 | chief financial officer |
2023-06-15 | PETERSON TYCHO | acquired | 104,594 | 7.3 | 14,328 | chief financial officer |
2023-06-15 | PETERSON TYCHO | sold | -597,100 | 8.53 | -70,000 | chief financial officer |
2023-06-02 | PETERSON TYCHO | sold | -272,080 | 7.16 | -38,000 | chief financial officer |
2023-04-11 | ADAMS R MARK | sold | -19,918 | 8.63 | -2,308 | chief operating officer |
2023-04-10 | ADAMS R MARK | sold | -6,944 | 8.5 | -817 | chief operating officer |
2023-03-27 | GRIFFIN MICHELLE RENEE | sold | -19,878 | 8.4913 | -2,341 | - |
Which funds bought or sold ADPT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | -108 | 342 | -% |
2023-09-07 | Triatomic Management LP | added | 58.26 | 136,999 | 813,024 | 0.83% |
2023-08-23 | Rappaport Reiches Capital Management, LLC | unchanged | - | -144,329 | 456,817 | 0.19% |
2023-08-22 | Asset Dedication, LLC | added | 5.44 | -3,000 | 8,000 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | unchanged | - | -43,248 | 136,884 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -64.56 | -333,907 | 123,052 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.63 | -297,174 | 845,393 | -% |
2023-08-18 | Legato Capital Management LLC | added | 39.55 | 38,287 | 671,248 | 0.09% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -39.11 | -5,817,430 | 5,009,570 | -% |
2023-08-15 | CAPTRUST FINANCIAL ADVISORS | added | 0.57 | -25,245 | 81,828 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
ADPT Alerts
Schedule 13G FIlings of Adaptive BioTech
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | blackrock inc. | 8.7% | 12,374,197 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 8.25% | 11,794,168 | SC 13G/A | |
| Sep 12, 2022 | price t rowe associates inc /md/ | 2.9% | 4,081,518 | SC 13G/A | |
| Feb 14, 2022 | viking global investors lp | 21.3% | 29,993,708 | SC 13G/A | |
| Feb 14, 2022 | matrix capital management company, lp | 8.20% | 11,572,590 | SC 13G/A | |
| Feb 10, 2022 | price t rowe associates inc /md/ | 9.4% | 13,286,713 | SC 13G | |
| Feb 10, 2022 | price t rowe associates inc /md/ | 10.0% | 14,240,614 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 7.82% | 11,031,288 | SC 13G/A | |
| Feb 16, 2021 | matrix capital management company, lp | 9.59% | 13,115,090 | SC 13G/A | |
| Feb 16, 2021 | viking global investors lp | 21.9% | 29,993,708 | SC 13G/A |
Recent SEC filings of Adaptive BioTech
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 01, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | 4 | Insider Trading | |
| Aug 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 02, 2023 | 8-K | Current Report | |
| Aug 02, 2023 | 10-Q | Quarterly Report | |
| Jul 03, 2023 | 8-K | Current Report | |
| Jun 21, 2023 | 4 | Insider Trading | |
| Jun 20, 2023 | 4 | Insider Trading | |
| Jun 20, 2023 | 144 | Notice of Insider Sale Intent | |
| Jun 15, 2023 | 144 | Notice of Insider Sale Intent |
Peers (Alternatives to Adaptive BioTech)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 33.0B | 7.0B | -5.38% | -12.23% | 29.09 | 4.71 | 5.03% | -14.68% |
MTD | 24.7B | 4.0B | -3.30% | -3.12% | 27.83 | 6.25 | 2.30% | 16.37% |
ILMN | 21.9B | 4.5B | -17.36% | -28.94% | -5.22 | 4.9 | -4.92% | -21931.58% |
TECH | 11.2B | 1.1B | -9.93% | -5.35% | 39.16 | 9.83 | 2.81% | 4.86% |
| MID-CAP | ||||||||
RGEN | 9.4B | 134.2M | 4.73% | -21.54% | 68.08 | 70.03 | -82.77% | -13.43% |
| SMALL-CAP | ||||||||
PACB | 2.4B | 146.1M | -8.89% | 61.75% | -7.4 | 16.16 | 4.72% | -55.19% |
QTRX | 960.9M | 112.0M | 5.18% | 169.83% | -14.6 | 8.58 | 0.83% | 16.42% |
ADPT | 749.3M | 189.6M | -19.57% | -31.57% | -3.92 | 3.95 | 18.74% | 17.75% |
HBIO | 175.0M | 114.1M | -1.44% | 44.37% | -32.24 | 1.53 | -5.49% | -48.58% |
CDXS | 118.7M | 99.2M | -1.73% | -74.89% | -2.09 | 1.2 | -26.56% | -199.52% |
CDXC | 103.3M | 80.9M | -10.97% | -2.13% | -15.91 | 1.28 | 17.20% | 77.07% |
BNGO | 99.7M | 31.5M | -1.32% | 40.85% | -0.68 | 3.16 | 35.12% | -38.47% |
NSTG | 73.7M | 143.9M | -41.73% | -89.43% | -0.44 | 0.51 | 0.71% | -18.99% |
CSBR | 72.1M | 52.7M | -20.39% | -41.08% | -9.55 | 1.37 | 2.10% | -1984.29% |
Adaptive BioTech News
Returns for ADPT
Cumulative Returns on ADPT
-51.8%
3-Year Cumulative Returns
Risks for ADPT
What is the probability of a big loss on ADPT?
98.7%
Probability that Adaptive BioTech stock will be more than 20% underwater in next one year
93.3%
Probability that Adaptive BioTech stock will be more than 30% underwater in next one year.
90.1%
Probability that Adaptive BioTech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ADPT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Adaptive BioTech was unfortunately bought at previous high price.
Drawdowns
Financials for Adaptive BioTech
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 2.9% | 189,601,000 | 184,335,000 | 185,308,000 | 168,040,000 | 159,677,000 | 154,522,000 | 154,344,000 | 146,599,000 | 133,431,000 | 115,914,000 | 98,382,000 | 92,406,000 | 92,165,000 | 93,315,000 | 85,071,000 | 78,054,000 | 69,184,000 | 58,614,000 | 55,663,000 | 57,512,000 | 46,272,000 |
| S&GA Expenses | -0.4% | 91,409,000 | 91,818,000 | 95,603,000 | 98,583,000 | 102,019,000 | 100,954,000 | 95,465,000 | 87,314,000 | 76,839,000 | 67,955,000 | 61,358,000 | 55,453,000 | 50,078,000 | 44,643,000 | 38,453,000 | 33,884,000 | 30,824,000 | 27,256,000 | 24,486,000 | 22,736,000 | 21,316,000 |
| R&D Expenses | -3.5% | 131,718,000 | 136,518,000 | 141,756,000 | 145,233,000 | 145,647,000 | 146,410,000 | 142,343,000 | 143,475,000 | 137,717,000 | 125,909,000 | 116,072,000 | 101,430,000 | 91,622,000 | 82,157,000 | 70,705,000 | 60,583,000 | 49,860,000 | 42,785,000 | 39,157,000 | 38,470,000 | 37,808,000 |
| EBITDA | - | - | - | - | - | -190,369,000 | -192,659,000 | -195,044,000 | - | - | -123,907,000 | -123,907,000 | -46,286,000 | -46,286,000 | -46,286,000 | -46,286,000 | - | - | - | - | - | - |
| EBITDA Margin | - | - | - | - | - | -1.19 | -1.25 | -1.26 | - | - | -1.07 | -1.26 | -0.50 | -0.50 | -0.50 | -0.54 | - | - | - | - | - | - |
| Interest Expenses | 9.8% | 11,374,000 | 10,358,667 | 4,238,000 | 2,612,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBT Margin | - | - | - | - | - | -1.30 | -1.34 | -1.34 | - | - | -1.26 | -1.49 | -0.74 | -0.74 | -0.74 | -0.81 | - | - | - | - | - | - |
| Net Income | 2.2% | -190,918,000 | -195,154,000 | -200,191,000 | -221,496,000 | -232,118,000 | -236,070,000 | -207,279,000 | -197,113,000 | -177,929,000 | -155,466,000 | -146,227,000 | -122,268,000 | -99,499,000 | -81,623,000 | -68,606,000 | -61,266,000 | -55,608,000 | -52,442,000 | -46,447,000 | -41,570,000 | -49,972,000 |
| Net Income Margin | 100.0% | - | -1.06 | -1.08 | -1.32 | -1.45 | -1.48 | -1.34 | -1.30 | -1.28 | -1.34 | -1.49 | -1.32 | -1.08 | -0.87 | -0.81 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -194,840,000 | -200,294,000 | -230,804,000 | -241,026,000 | -247,917,000 | -254,473,000 | -240,616,000 | -233,917,000 | -208,003,000 | -168,486,000 | -148,479,000 | -130,684,000 | -114,837,000 | 194,204,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 | 2017Q4 |
| Assets | -3.4% | 765 | 791 | 857 | 884 | 807 | 858 | 923 | 993 | 1,033 | 1,072 | 1,116 | 1,095 | 855 | 875 | 912 | 917 | 601 | 333 | 362 |
| Current Assets | -4.9% | 477 | 501 | 562 | 564 | 439 | 419 | 403 | 467 | 644 | 765 | 727 | 877 | 600 | 585 | 613 | 601 | 442 | 181 | 205 |
| Cash Equivalents | 15.5% | 109 | 95.00 | 90.00 | 218 | 76.00 | 115 | 139 | 122 | 184 | 174 | 123 | 497 | 365 | 213 | 97.00 | 75.00 | 48.00 | 55.00 | 85.00 |
| Inventory | -4.6% | 19.00 | 20.00 | 14.00 | 17.00 | 19.00 | 21.00 | 19.00 | 18.00 | 19.00 | 17.00 | 14.00 | 11.00 | 11.00 | 11.00 | 9.00 | 9.00 | 8.00 | 8.00 | 5.00 |
| Net PPE | -2.3% | 79.00 | 81.00 | 83.00 | 87.00 | 87.00 | 86.00 | 85.00 | 88.00 | 75.00 | 56.00 | 40.00 | 31.00 | 27.00 | 25.00 | 60.00 | 47.00 | 22.00 | 19.00 | 14.00 |
| Goodwill | 0% | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 |
| Liabilities | 0.3% | 369 | 368 | 393 | 396 | 288 | 305 | 319 | 341 | 340 | 346 | 373 | 320 | 325 | 323 | 341 | 331 | 324 | 30.00 | 26.00 |
| Current Liabilities | 5.8% | 95.00 | 90.00 | 110 | 104 | 111 | 115 | 114 | 122 | 117 | 107 | 105 | 101 | 93.00 | 78.00 | 78.00 | 73.00 | 75.00 | 23.00 | 21.00 |
| Shareholder's Equity | -6.6% | 396 | 424 | 464 | 488 | 518 | 553 | 604 | 652 | 693 | 726 | 743 | 775 | 530 | 552 | 571 | 586 | - | - | - |
| Retained Earnings | -4.9% | -1,024 | -976 | -919 | -878 | -833 | -781 | -718 | -657 | -601 | -552 | -511 | -467 | -430 | -396 | -365 | -344 | -330 | -295 | -249 |
| Additional Paid-In Capital | 1.3% | 1,422 | 1,403 | 1,387 | 1,373 | 1,358 | 1,340 | 1,324 | 1,309 | 1,295 | 1,277 | 1,254 | 1,241 | 958 | 945 | 936 | 930 | 46.00 | 38.00 | 25.00 |
| Shares Outstanding | 0.3% | 145 | 144 | 143 | 143 | 142 | 142 | 141 | 141 | 140 | 139 | 138 | 129 | 127 | 126 | 69.00 | 51.00 | 13.00 | 13.00 | 12.00 |
| Minority Interest | -1.5% | -0.07 | -0.07 | -0.07 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 13.2% | -155,135 | -178,644 | -183,945 | -207,752 | -208,787 | -198,935 | -192,727 | -178,745 | -182,458 | -176,322 | -149,683 | -136,630 | -119,612 | -104,505 | 205,404 | 226,785 | 245,237 | 348,276 | -32,259 | -46,744 | -30,326 |
| Share Based Compensation | 5.5% | 60,452 | 57,287 | 55,477 | 53,058 | 50,559 | 47,628 | 43,251 | 38,619 | 33,446 | 28,570 | 24,761 | 20,929 | 17,759 | 14,718 | 13,124 | 12,724 | 11,977 | 11,045 | 11,149 | 9,906 | 9,600 |
| Cashflow From Investing | 115.5% | 60,773 | 28,196 | 2,905 | 167,661 | 88,378 | 125,079 | 181,210 | -226,051 | -302,029 | -165,984 | -117,044 | 269,685 | 106,079 | -116,762 | -481,697 | -500,748 | -234,763 | -252,552 | 736 | 20,532 | -64,052 |
| Cashflow From Financing | -1.9% | 127,667 | 130,188 | 132,265 | 135,537 | 12,943 | 15,281 | 27,146 | 30,121 | 303,233 | 303,242 | 293,587 | 289,080 | 332,592 | 324,751 | 319,916 | 318,448 | -1,045 | 612 | 1,248 | 228 | 1,826 |
ADPT Income Statement
2023-06-30Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenue | $ 48,926 | $ 43,660 | $ 86,573 | $ 82,280 |
| Operating expenses | ||||
| Cost of revenue | 17,910 | 13,221 | 36,591 | 26,413 |
| Research and development | 32,237 | 37,037 | 64,838 | 74,876 |
| Sales and marketing | 23,872 | 24,281 | 46,180 | 50,374 |
| General and administrative | 22,302 | 21,200 | 43,133 | 45,344 |
| Amortization of intangible assets | 423 | 423 | 842 | 842 |
| Total operating expenses | 96,744 | 96,162 | 191,584 | 197,849 |
| Loss from operations | (47,818) | (52,502) | (105,011) | (115,569) |
| Interest and other income, net | 3,612 | 418 | 6,636 | 689 |
| Interest expense | (3,605) | (7,136) | ||
| Net loss | (47,811) | (52,084) | (105,511) | (114,880) |
| Add: Net loss attributable to noncontrolling interest | 1 | 38 | 2 | 98 |
| Net loss attributable to Adaptive Biotechnologies Corporation | $ (47,810) | $ (52,046) | $ (105,509) | $ (114,782) |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | $ (0.33) | $ (0.37) | $ (0.73) | $ (0.81) |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | 144,397,693 | 142,363,589 | 143,956,867 | 142,032,261 |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | $ (0.33) | $ (0.37) | $ (0.73) | $ (0.81) |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | 144,397,693 | 142,363,589 | 143,956,867 | 142,032,261 |
ADPT Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 109,240 | $ 90,030 |
| Short-term marketable securities (amortized cost of $308,885 and $412,282, respectively) | 307,990 | 408,166 |
| Accounts receivable, net | 31,545 | 40,057 |
| Inventory | 18,960 | 14,453 |
| Prepaid expenses and other current assets | 9,074 | 9,440 |
| Total current assets | 476,809 | 562,146 |
| Long-term assets | ||
| Property and equipment, net | 79,390 | 83,447 |
| Operating lease right-of-use assets | 77,109 | 80,763 |
| Restricted cash | 2,923 | 2,398 |
| Intangible assets, net | 5,985 | 6,827 |
| Goodwill | 118,972 | 118,972 |
| Other assets | 3,352 | 2,064 |
| Total assets | 764,540 | 856,617 |
| Current liabilities | ||
| Accounts payable | 9,163 | 8,084 |
| Accrued liabilities | 8,356 | 12,424 |
| Accrued compensation and benefits | 10,554 | 15,935 |
| Current portion of operating lease liabilities | 9,345 | 9,230 |
| Current portion of deferred revenue | 57,917 | 64,115 |
| Total current liabilities | 95,335 | 109,788 |
| Long-term liabilities | ||
| Operating lease liabilities, less current portion | 94,176 | 98,772 |
| Deferred revenue, less current portion | 50,895 | 58,599 |
| Revenue interest liability, net | 128,167 | 125,360 |
| Total liabilities | 368,573 | 392,519 |
| Commitments and contingencies (Note 9) | ||
| Shareholders’ equity | ||
| Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022 | ||
| Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2023 and December 31, 2022; 144,645,118 and 143,105,002 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 14 | 14 |
| Additional paid-in capital | 1,421,506 | 1,387,349 |
| Accumulated other comprehensive loss | (893) | (4,116) |
| Accumulated deficit | (1,024,591) | (919,082) |
| Total Adaptive Biotechnologies Corporation shareholders’ equity | 396,036 | 464,165 |
| Noncontrolling interest | (69) | (67) |
| Total shareholders’ equity | 395,967 | 464,098 |
| Total liabilities and shareholders’ equity | $ 764,540 | $ 856,617 |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.